| iASPP preferentially binds p53 proline-rich region and modulates apoptotic function of codon 72–polymorphic p53 D Bergamaschi, Y Samuels, A Sullivan, M Zvelebil, H Breyssens, A Bisso, ... Nature genetics 38 (10), 1133-1141, 2006 | 335 | 2006 |
| Pin1 and WWP2 regulate GluR2 Q/R site RNA editing by ADAR2 with opposing effects R Marcucci, J Brindle, S Paro, A Casadio, S Hempel, N Morrice, A Bisso, ... The EMBO journal 30 (20), 4211-4222, 2011 | 147 | 2011 |
| Oncogenic miR-181a/b affect the DNA damage response in aggressive breast cancer A Bisso, M Faleschini, F Zampa, V Capaci, J De Santa, L Santarpia, ... Cell cycle 12 (11), 1679-1687, 2013 | 143 | 2013 |
| Cooperation between MYC and β‐Catenin in liver tumorigenesis requires Yap/Taz A Bisso, M Filipuzzi, GP Gamarra Figueroa, G Brumana, F Biagioni, ... Hepatology 72 (4), 1430-1443, 2020 | 64 | 2020 |
| Mutant p53 induces Golgi tubulo-vesiculation driving a prometastatic secretome V Capaci, L Bascetta, M Fantuz, GV Beznoussenko, R Sommaggio, ... Nature communications 11 (1), 3945, 2020 | 60 | 2020 |
| Peptide aptamers targeting mutant p53 induce apoptosis in tumor cells E Guida, A Bisso, C Fenollar-Ferrer, M Napoli, C Anselmi, JE Girardini, ... Cancer research 68 (16), 6550-6558, 2008 | 58 | 2008 |
| MYC in germinal center‐derived lymphomas: mechanisms and therapeutic opportunities A Bisso, A Sabò, B Amati Immunological reviews 288 (1), 178-197, 2019 | 51 | 2019 |
| YAP and TAZ are dispensable for physiological and malignant haematopoiesis E Donato, F Biagioni, A Bisso, M Caganova, B Amati, S Campaner Leukemia 32 (9), 2037-2040, 2018 | 49 | 2018 |
| p73 as a pharmaceutical target for cancer therapy A Bisso, L Collavin, G Del Sal Current Pharmaceutical Design 17 (6), 578-590, 2011 | 46 | 2011 |
| Pin1 is required for sustained B cell proliferation upon oncogenic activation of Myc L D'Artista, A Bisso, A Piontini, M Doni, A Verrecchia, TR Kress, MJ Morelli, ... Oncotarget 7 (16), 21786, 2016 | 31 | 2016 |
| αβ-T cells engineered to express γδ-T cell receptors can kill neuroblastoma organoids independent of MHC-I expression JGM Strijker, R Pscheid, E Drent, JJF van der Hoek, B Koopmans, K Ober, ... Journal of personalized medicine 11 (9), 923, 2021 | 9 | 2021 |
| Decoding YAP dependent transcription in the liver F Biagioni, O Croci, S Sberna, E Donato, A Sabò, A Bisso, L Curti, ... Nucleic Acids Research 50 (14), 7959-7971, 2022 | 7 | 2022 |
| Polycomb group ring finger protein 6 suppresses Myc-induced lymphomagenesis N Tanaskovic, M Dalsass, M Filipuzzi, G Ceccotti, A Verrecchia, P Nicoli, ... Life Science Alliance 5 (8), 2022 | 4 | 2022 |
| Targeting solid tumors with GDT002, a first-in-class γδTCR-based T cell therapy E Drent, A Bisso, S Baardman, D Verweij, E Salcedo, C Coomans, ... Cancer Research 82 (12_Supplement), 2818-2818, 2022 | 2 | 2022 |
| Editor's Note: Peptide Aptamers Targeting Mutant p53 Induce Apoptosis in Tumor Cells E Guida, A Bisso, C Fenollar-Ferrer, M Napoli, C Anselmi, JE Girardini, ... Cancer Research 82 (9), 1844-1844, 2022 | 1 | 2022 |
| Cooperation between MYC and β-catenin in liver tumorigenesis requires Yap/Taz A Bisso, M Filipuzzi, GP Gamarra Figueroa, G Brumana, F Biagioni, ... bioRxiv, 819631, 2019 | 1 | 2019 |
| A patient-derived organoid platform to assess the effectiveness of γδTCR cell therapy in solid tumors A Bisso, R Overmeer, S Baardman, C Coomans, C Oyarce, SF Boj Cancer Research 84 (6_Supplement), 3611-3611, 2024 | | 2024 |
| Immunotherapy: TARGETING OVARIAN CARCINOMA WITH GDT002, A FIRST-IN-CLASS γδTCR-BASED T CELL THERAPY S Middendorp, E Drent, A Bisso, S Baardman, D Verweij, E Salcedo, ... Cytotherapy 25 (6), S240, 2023 | | 2023 |
| 215 Targeting ovarian carcinoma with GDT002, a first-in-class γδTCR-based T cell therapy E Drent, S Middendorp, A Bisso, S Baardman, D Verweij, E Salcedo, ... Journal for ImmunoTherapy of Cancer 10 (Suppl 2), 2022 | | 2022 |
| P06. 01 αβ-T cells engineered to express γδ-T cell receptors can kill neuroblastoma organoids independent of MHC-I expression JGM Strijker, E Drent, JJF van der Hoek, R Pscheid, B Koopmans, K Ober, ... Journal for ImmunoTherapy of Cancer 9 (Suppl 1), 2021 | | 2021 |
